Asthma Research and Practice

We are delighted to announce that Asthma Research and Practice has launched a new allergy section that is now open to submissions! The section is edited by Dr Olympia Tsilochristou MD PhD, Consultant Allergist and considers all aspects of allergy with a particular focus on links between asthma and allergic rhinitis, drug hypersensitivity reactions, and food allergy as well as on allergen immunotherapy and biologicals for asthma/allergic rhinitis. If you would like more information on the section’s aims and scopes or on the suitability of your manuscript for the journal, please do reach out using the Contact button at the bottom of the page.

Around 5–10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been launched and several asthma phenotypes according to definite biomarkers have been identified. In particular, therapy with biologics has revolutionized the management and the treatment of severe asthma, showing high therapeutic efficacy associated with significant clinical benefits. The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.

Read the article